A Study of a New PET Scanner in People With Cancer
The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn whether this scanner can produce better PET/CT images and provide more useful imaging information than standard PET/CT scanners.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Oct 9, 2026 · Source: ClinicalTrials.gov
The study is currently accepting participants.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Interventions being studied
- Diagnostic Test: Biograph Vision Quadra scanner; Diagnostic Test: PET/CT
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Eligibility Criteria for objective #1:
- Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules.
- Patients who are undergoing a planned PET-CT scan at main campus of MSK.
- Patients must be ≥ 18 years old Eligibility Criteria for objective #2:
- Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously.
- Patients with metastatic prostate or head and neck cancer.
- Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK.
- Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK
- Patients must be ≥ 18 years old Eligibility Criteria for objective #3:
- Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer).
- Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an \[18F\]-fluormisonidazole PET-CT scan at the main campus of MSK.
- Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection)
- Patients must be ≥ 18 years old Eligibility Criteria for objective #4:
- Patients who are undergoing a planned PET-CT scan at main campus of MSK with a radiotracer
- Patients must be ≥ 18 years old
- Patients who suffer from claustrophobia.
- Women who are pregnant or breast-feeding.
- Patients \< 18 years of age
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Memorial Sloan Kettering Basking Ridge (Consent Only)Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Consent Only)Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Consent Only )Montvale, New Jersey
- Memorial Sloan Kettering Suffolk-Commack (Consent Only)Commack, New York
- Memorial Sloan Kettering Westchester (Consent Only)Harrison, New York
- Memorial Sloan Kettering Cancer CenterNew York, New York
- Memorial Sloan Kettering Nassau (Consent Only)Rockville Centre, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 9, 2026. Always confirm current availability with the study team.